This article provides a comprehensive overview of Tempest Therapeutics Inc’s (TPST) financial performance, including its income statement, balance sheet, and cash flow statement. It highlights key financial metrics for fiscal year 2024, such as negative net income, free cash flow, and EBITDA, along with financial health signals like a low Piotroski F-Score and concerns about earnings quality and interest coverage. The analysis covers both annual and quarterly data, derived from SEC filings.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
TPST Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Tempest Therapeutics Inc’s (TPST) financial performance, including its income statement, balance sheet, and cash flow statement. It highlights key financial metrics for fiscal year 2024, such as negative net income, free cash flow, and EBITDA, along with financial health signals like a low Piotroski F-Score and concerns about earnings quality and interest coverage. The analysis covers both annual and quarterly data, derived from SEC filings.